Researchers have found in a new research that HLA-B27 genetic marker is linked to a higher risk of various arthropathies, ...

One of the worst complications of adult-onset Still's disease is macrophage activation syndrome (MAS), which can be fatal. In ...

Bio-Thera Solutions, the developer of the biosimilar, will continue to hold manufacturing rights in the US market.

Patients with juvenile idiopathic arthritis (JIA) who carried the HLA-B27 genetic marker tended to have worse long-term ...

Indian paediatric rheumatologists discuss early diagnosis and management of rheumatic disorders in children to prevent organ ...

HLA-B27 positivity is linked to higher odds of non-remission in patients with juvenile idiopathic arthritis at 18 years after ...

Organon (NYSE:OGN) announced Tuesday the acquisition of regulatory and commercial rights linked to Tofidence, a biosimilar ...

The most prevalent type of arthritis in children and teenagers under the age of sixteen is called juvenile idiopathic ...

Tofidence is indicated in certain patients for the treatment of moderate to severe rheumatoid arthritis, giant cell arteritis ...

Originally approved by the FDA in September 2023, Biogen's Tofidence became the first tocilizumab biosimilar available in the ...

Organon (OGN) announced that it has acquired from Biogen (BIIB) regulatory and commercial rights in the U.S. for Tofidence, a biosimilar to ...

to evaluate if intravenous infusion affects signs and symptoms of oligoarticular or polyarticular juvenile idiopathic arthritis (JIA) and improve quality of life in suffering children aged 2 ...